Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

completed350%
terminated117%
unknown117%
not_yet_recruiting117%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruiting

KSD-101 in Patients With EBV-associated Hematological Malignancies

NCT07525024
terminatedphase_2

Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.

NCT02718391
unknownphase_1

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

NCT01883518
completedphase_1

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

NCT01530698
completedphase_2

Immunization Against Tumor Cells in Sezary Syndrome

NCT00099593
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07525024

KSD-101 in Patients With EBV-associated Hematological Malignancies

Not Yet Recruiting
NCT02718391Phase 2

Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.

Terminated
NCT01883518Phase 1

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

Unknown
NCT01530698Phase 1

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

Completed
NCT00099593Phase 2

Immunization Against Tumor Cells in Sezary Syndrome

Completed
NCT00243529Phase 1

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6